Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates

BACKGROUND: Patients with glucocorticoid-induced osteoporosis (GIOP) are at very high risk of fracture, and patients with severe GIOP often experience fractures during treatment with bisphosphonates. Teriparatide (TPTD) is the only currently available anabolic agent expected to be effective for GIOP...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Springerplus
Autors principals: Seno, Takahiro, Yamamoto, Aihiro, Kukida, Yuji, Hirano, Aiko, Kida, Takashi, Nakabayashi, Amane, Fujioka, Kazuki, Nagahara, Hidetake, Fujii, Wataru, Murakami, Ken, Oda, Ryo, Fujiwara, Hiroyoshi, Kohno, Masataka, Kawahito, Yutaka
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2016
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4940355/
https://ncbi.nlm.nih.gov/pubmed/27462504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-016-2704-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars